Physician profile
Jeffrey Perlmutter
NPI 1588651889
$6,995.72
in general payments reported to CMS, 2019-2025
15 companies · $3,025 in 2025
The $3,025 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.35 · 2021: $99.09 · 2022: $261 · 2023: $149 · 2024: $3,392 · 2025: $3,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $2,981 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,400 · Food and Beverage: $883 · Travel and Lodging: $282 · Education: $19.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $2,980.76 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,400.00 |
| Food and Beverage | $882.88 |
| Travel and Lodging | $282.06 |
| Education | $19.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $3,227.57 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $3,063.23 | 2019-2025 | Lokelma |
| Vifor Pharma, INC. | $169.37 | 2019-2025 | Veltassa |
| Amgen INC. | $76.08 | 2022-2023 | Tavneos |
| Vertex Pharmaceuticals Incorporated | $73.24 | 2022 | |
| Sonavex, INC. | $63.54 | 2023 | Echosure |
| Bayer Healthcare Pharmaceuticals INC. | $52.37 | 2021-2024 | |
| Ardelyx, INC. | $50.21 | 2023-2024 | Ibsrela |
| Travere Therapeutics, INC. | $46.88 | 2023-2024 | |
| Calliditas Therapeutics US INC. | $46.63 | 2024-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $35.64 | 2023-2024 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $33.42 | 2019 | |
| Akebia Therapeutics INC | $21.53 | 2021 | |
| Opko Pharmaceuticals, LLC | $19.25 | 2021 | |
| Genzyme Corporation | $16.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Perlmutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.